Phaseline

Targets › DNASE1

DNASE1 (Deoxyribonuclease-1): drug programs, companies and trials

7 programs from 7 companies in 7 trials: 3 Phase 2, 2 Phase 4, 1 Phase 1, 1 Phase 3; Infectious disease, Neurology, Oncology; next expected readout Jul 2027.

Serum endocuclease secreted into body fluids by a wide variety of exocrine and endocrine organs. Expressed by non-hematopoietic tissues and preferentially cleaves protein-free DNA (By similarity). (UniProt, P24855)

Open in Phaseline: the race on DNASE1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of North Carolina, Chapel HillDeoxyribonuclease (DNase)
DNA degradation enzyme; degrades extracellular DNA in biofilms to reduce viscosity
DNASE1Phase 4Pleural Infection BacterialSep 2028
Amsterdam UMCDNase
Deoxyribonuclease - breaks down extracellular DNA in biofilms
DNASE1Phase 4Empyema, PleuralOct 2028
University Hospital, Strasbourg, FranceDornase Alfa Inhalant Solution [Pulmozyme]
Recombinant deoxyribonuclease (DNase) that degrades nucleic acids in DAMPs and neutrophil
DNASE1Phase 3Multiple TraumaSep 2027
National Cancer Institute, Slovakiadornase alfa
recombinant human DNase I that degrades extracellular DNA and restores DNA homeostasis
DNASE1Phase 2Refractory Germ Cell TumorsJul 2027
Ludwig-Maximilians - University of MunichDornase Alfa
DNase 1 (deoxyribonuclease 1) - endonuclease that cleaves extracellular DNA to reduce syst
DNASE1Phase 2Ischemic StrokeMar 2028
Jon SimmonsPulmozyme / Recombinant human deoxyribonuclease (rh-DNase)
Recombinant human DNase that cleaves extracellular DNA, reducing mucus viscosity and airwa
DNASE1Phase 2Covid19–
McMaster UniversityIntravenous DNase I
DNase I enzyme; cleaves extracellular DNA in neutrophil extracellular traps (NETs)
DNASE1Phase 1Sepsis–

Conditions

Pleural Infection Bacterial (1) Sepsis (1) Empyema, Pleural (1) Ischemic Stroke (1) Covid19 (1) Refractory Germ Cell Tumors (1) Multiple Trauma (1)

Modalities

mixed (4), protein or peptide (2), small molecule (1)

Companies

University of North Carolina, Chapel Hill (1) McMaster University (1) Amsterdam UMC (1) Ludwig-Maximilians - University of Munich (1) Jon Simmons (1) National Cancer Institute, Slovakia (1) University Hospital, Strasbourg, France (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.